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Generally, transfusion of blood components is a safe
and often life-saving procedure. However, there are
instances when transfusion can lead to an adverse out-
come and even death. These fatalities may result from
“transfusion reactions,” the transmission of infectious
agents that lead to, for example, acquired immunodefi-
ciency syndrome (AIDS), hepatitis, or disease states
induced by transfusion in susceptible persons, such as
posttransfusion purpura (PTP) or iron overload.
This article limits this discussion to those events com-
monly referred to as transfusion reactions, specifically,
hemolysis, acute and delayed; febrile reactions; anaphy-
laxis; sepsis; acute lung injury; transfusion-associated
graft-versus-host disease; and transfusion-associated cir-
culatory overload. For further discussion of transfusion-
transmitted infectious disease, PTP, and iron overload, the
reader is referred to the transfusion medicine literature.
Hemolysis
The evaluation of acute transfusion reactions is dis-
cussed in detail in many texts and manuals. However,
some basic facts that the transfusionist must know are
as follows: 
• Stop the transfusion as soon as a reaction is sus-
pected. This limits the amount of the blood compo-
nent the patient receives. 
• The IV line should be kept open with 0.9% sodium
chloride, and all blood products and patient IDs
should be checked.
• The transfusion service should be notified and sent
appropriate samples, as listed in Table 1.
minations by observing the blood component, tubing,
and IV solutions. Hemolysis in the blood bag shows that
damage occurred before the blood reached the patient.
Improper storage temperature or contamination might
be the cause. If hemolysis is observed in the tubing but
not in the bag, there may have been a hypotonic solution
used in the administration set or a faulty blood warmer. 
Acute Hemolytic Transfusion Reactions
In all discussions of transfusion reactions, first and
foremost discussed are acute hemolytic transfusion reac-
tions (HTRs). These occur because of antibodies in the
recipient against antigens on the red blood cells (RBCs)
being transfused. This antigen-antibody reaction acti-
vates complement, the coagulation cascade, the kinen
system, and cytokines, which in turn may result in dis-
seminated intravascular coagulation (DIC), shock, renal
failure, and death. Most life-threatening reactions of this
type are caused by serologic incompatibility in the ABO
system. These reactions, which can have an onset with-
in minutes, are primarily due to IgM antibodies that bind
complement and, as a consequence, produce intravas-
cular hemolysis. However, fatal hemolysis due to IgG
antibodies from other blood group systems does occur,
even though these reactions are generally less severe
than those mediated by IgM antibodies in the ABO sys-
tem. IgG antibodies, such as those in the Rh system, do
not usually bind complement and they cause extravas-
cular hemolysis. 
The most common initial signs of an acute HTR are
fever and chills, but chest pain, nausea, flushing, dysp-
nea, generalized bleeding, back pain, and other nonspe-
cific symptoms may occur. As little as 10 mL of
incompatible blood can cause a reaction, but clinical
severity is proportional to the volume infused. In an
anesthetized patient, excessive bleeding is often the first
sign of an acute HTR. Emergency treatment must be
started as soon as possible to ameliorate the life-threat-
ening sequelae that may ensue. While awaiting confir-
mation from the blood bank, this diagnosis must often
be made based on the clinical picture and available evi-
dence. Patients should be moved to an intensive care
unit so that close monitoring can take place. Aggressive
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Table 1. Items to be sent to the blood bank laboratory for transfusion 
reaction investigation
Items Send to
Blood samples To transfusion service for 
Red top tube (no serum separators) serologic evaluation
Lavender top (EDTA) tube
Urine sample To chemistry to test for
hemoglobin
All tags and paperwork, the adminis- To transfusion service for 
tration set (needle removed), and clerical check and evaluation
IV solutions of non-immune hemolysis
Not all hemolysis is caused by immune mechanisms,
and the transfusion service can often make such deter-
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fluid replacement is necessary to treat the hypotension
and shock. Diuretics are often part of the treatment.
Intravenous furosemide will increase renal blood flow.
Mannitol, an osmotic diuretic, increases the blood vol-
ume and might indirectly increase urine output. If vaso-
pressors are needed, dopamine is the best choice
because of its dilatory effects on the renal vasculature
when used in doses of 1–5 μg/kg/min.
In recent years the study of biologic mediators, called
cytokines, has been a triumph in our understanding of
inflammation, immune response, hematopoesis,
hemostasis, and shock. This group of soluble glycopro-
teins regulates intercellular communication, and can be
pyrogens in addition to their many other effects. They
act over short distances and interact with other cells via
high-affinity cell surface receptors, sending a signal
across the cell membrane, thus activating intracellular
biochemical pathways. This is how cytokines work in
hematopoesis when they bind to receptors on bone
marrow stem cells, and how they maintain our immu-
nity in working order by binding to receptors on lym-
phocytes, natural killer cells, and mononuclear
phagocytes.1 Unfortunately, the pro-inflammatory sub-
set of cytokines may also be the culprits in much of the
symptomatology seen in a variety of transfusion reac-
tions.
A series of studies has created experimental models
of HTRs, illustrating the role that cytokines play. (See
Table 2 for an overview of the cytokines and some of
tance in elaborating cytokines, and also cause expres-
sion of procoagulant activity through the factor VII–
tissue factor pathway (see below). A heat-sensitive fac-
tor in plasma, consistent with complement, is necessary
in all of the above reactions except the generation of
MCP-1.2–5
While all of the former reactions were observed in
vitro, a chance to authenticate these observations in
vivo occurred serendipitously in a 47-year-old man par-
ticipating in a study of activation of the inflammatory
response by bypass surgery.6 He was group O, D+, and
100 mL of group A, D+ blood was given by accident
immediately after surgery. Postoperative TNF was 27.8
pg/mL, but following transfusion the TNF rose to 387.8
pg/mL, and 48 hours later was still 133.3 pg/mL. The
other patients in the study did not have a postoperative
increase in TNF. 
TNF is a multifunctional cytokine that also affects the
endothelial cells. The result is to decrease thrombo-
modulin, a protein that enhances anticoagulation
(through protein C). TNF also causes the endothelial
cells to increase tissue factor production. Tissue factor
is a lipoprotein that activates factors that lead to coagu-
lation. Thus, TNF most likely triggers DIC in hemolytic
reactions, both by driving coagulation and inhibiting
anticoagulation.7
In vitro models of the extravascular hemolysis seen
with IgG antibodies have also been constructed by incu-
bating IgG-coated RBCs with monocyte suspensions.
Interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and inter-
leukin-8 (IL-8) were increased in one study,8 while TNF
was more significantly elevated in another.9 IL-1ß has
many biologic effects, including fever, malaise, T and B
cell activation, and, in high enough concentrations,
hypotension and shock (see Table 2). Both studies
showed the presence of erythrophagocytosis, and with
immunocytochemical stains it was shown that mono-
cytes that had ingested RBCs were the cells producing
cytokines.8 In extravascular hemolysis, the coated cells
are removed this way in the spleen and in the liver. In
addition, an IL-1 receptor antagonist (IL-1ra) exists,
which inhibits the activity of IL-1 by competing for
receptor sites. Its production is also stimulated by IgG-
coated RBCs.10
In 1977, Goldfinger11 pointed out that acute HTRs
are an iatrogenic disease, thus we should recognize
them early and act to block the complications. We must
understand that this transfusion complication is not only
the most likely to result in death but usually could have
Table 2. Cytokines in transfusion reactions
Name Abbreviation Actions
Interleukin-1ß IL-1ß pyrogen; causes hypotension; 
activates T and B lymphocytes
Interleukin-6 IL-6 pyrogen; essential for Ig 
production by B lymphocytes
Interleukin-8 IL-8 neutrophil chemotactic and 
activating factor
Tumor necrosis factor TNF pyrogen; causes hypotension;
decreases thrombomodulin and 
increases tissue factor 
Monocyte MCP-1 monocyte chemotactic and
chemoattractant activating factor
protein-1
their actions.) Early in the course of ABO incompatibili-
ty, tumor necrosis factor (TNF) is produced, causing
fever and hypotension. Interleukin-8 (IL-8) and mono-
cyte chemoattractant protein-1 (MCP-1) follow. IL-8 caus-
es neutrophil chemotaxis and neutrophil activation,
while MCP-1 acts in a similar manner on monocytes.
Mononuclear phagocytes seem to be of prime impor-
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clusion drawn from this is that the autologous as well as
allogenic RBCs become sensitized in a DSTR.




Febrile non-hemolytic transfusion reactions
(FNHTRs) are the most frequent complication of RBC
and platelet therapy, and consist of an increase in tem-
perature of at least 1°C in association with transfusion,
without any other cause. These reactions are more com-
mon in multiply transfused patients or multiparous
women, because these patients are more likely to have
antibodies to transfused white blood cells (WBCs),
which are often the cause of these reactions. These
leukocytes are in the product incidentally, and are of no
therapeutic benefit. Antipyretics are an effective treat-
ment and the reaction is not serious. However, since
fever is the initial sign of the more ominous hemolytic
reactions already discussed, it is necessary to stop the
transfusion and proceed with a blood bank evaluation.
Other more serious causes of temperature elevation,
such as hemolysis or bacterial contamination, will then
be ruled out. FNHTRs are actually diagnosed by the
exclusion of other causes of fever. 
Not all patients who have this type of reaction will
have it again after subsequent transfusions, and the reac-
tion may be prevented entirely by the use of antipyret-
ics as pretreatment. However, after a second reaction it
is common practice to issue leukocyte-reduced prod-
ucts. This strategy reduces the occurrence of FNHTRs,
but does not eliminate all of them, and is more likely to
be of benefit with the transfusion of red cells (RBCs)
than with the transfusion of platelets.14 The reason for
the persistence of these reactions, even after leukocyte
reduction, may be the production of cytokines.
However, the cytokines are produced by donor leuko-
cytes in the product, rather than by the recipient at the
time of transfusion, as was described in hemolytic reac-
tions above. 
Heddle et al.15 first demonstrated that the age of
platelet products, as well as the leukocyte count, corre-
lated with the likelihood of a febrile reaction. A subse-
quent study showed that the supernatant portion of the
platelet concentrate (PC) was more likely to cause a
reaction than the cellular portion, and when a reaction
occurred, there was a positive correlation with high
concentrations of IL-1ß and IL-6.16 Other studies also
been avoided. During the first 10 years of mandatory
reporting of transfusion-associated deaths to the Food and
Drug Administration (FDA), the deaths due to acute
hemolytic reactions caused by “blood given to the wrong
person” accounted for 49 percent of the total number of
deaths. Errors existed at all stages of identification, from
the time of phlebotomy to the time of transfusion.12
Delayed Hemolytic Transfusion Reactions
Delayed hemolytic transfusion reactions (DHTRs)
occur when a transfusion recipient has already been
immunized, but the antibody is not detected in pre-
transfusion testing. This results in an anamnestic
response. Reasons for this include antibodies that have
not yet developed to a detectable level, or antibodies
that have fallen to an undetectable level (a distinction the
antibodies in the Kidd system enjoy). 
The primary immunization event may also be consid-
ered a DHTR. However, the antibodies appear late after
the transfusion and are often of low titer, causing little or
no hemolysis. Even if the titer is actually high enough,
there might not be enough transfused RBCs left in the
circulation to produce any detectable hemolysis. 
Patients with DHTRs can manifest fever, hemoglobin-
uria, bilirubinemia, or even mild jaundice. However,
these symptoms, if they occur at all, may be dismissed as
being due to the patient’s underlying disease. Renal fail-
ure is very rare, but if the patient is compromised sec-
ondarily to his or her condition, then monitoring the
urine output and renal function is important. Failure to
find the expected increase in hemoglobin level may be
the only symptom detected by the clinical team. The
blood bank detecting the antibody when the next blood
transfusion is ordered is by far the most common
method of diagnosis. Indeed, this might be the only way
possible if the clinical features are not present.
The typical serologic picture is usually found 3 to 7
days after transfusion and consists of a newly positive
direct antiglobulin test (DAT) with IgG antibody and/or
complement (which may be mixed-field), and a new
alloantibody in the eluate and/or serum. Ness et al.13
suggest that the term that is most apropos, when the
above serologic picture is present without the clinical
features, is delayed serologic transfusion reaction
(DSTR).13 This is an important distinction because the
frequency of DSTRs is higher than that of DHTRs.
In addition, Ness’s study showed that the DAT
remained positive after the sensitized cells were expect-
ed to have been cleared from the circulation.13 One con-
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proved that increased levels of TNF, IL-1, IL-6,17 and IL-
818 in platelets with longer storage time presented a
greater risk for FNHTRs.17 Prestorage filtration was
shown to prevent the production of cytokines in the
products during storage.18,19 Cytokines increase in the
supernatant portion of RBCs during storage, although
they do not reach the levels observed in platelet con-
centrates.20 However, RBCs also are less likely to pro-
duce FNHTRs if WBC levels are reduced before storage
rather than after storage.21
Conclusions based on the data in these papers are
that monocytes remain metabolically active during stor-
age, and produce cytokines that will be released into the
product. Monocytes make up a large percentage of the
WBCs, as opposed to RBCs in PCs, and are more active
in this product, because of the higher storage tempera-
ture. Bedside filtration to remove leukocytes will not
remove the offending agents, which are soluble in the
supernatant portion. The only realistic way to protect




Life-threatening anaphylactic reactions may occur
within minutes after the infusion of only a few mL of
blood. The patient may exhibit coughing, bron-
chospasm, and respiratory distress, followed by vascu-
lar collapse and shock. Fever is absent, but flushing of
the skin and gastrointestinal symptoms such as nausea,
vomiting, or diarrhea may occur. The absence of IgA,
which occurs in approximately 1 in 700 persons, can be
responsible; however, the recipient must also have anti-
IgA present, so the actual occurrence is substantially
lower than 1 in 700. Previous pregnancy or transfusion
might account for the presence of anti-IgA, but in some
people who have anti-IgA and in whom IgA is absent,
the immunizing event is never discovered. The anti-
bodies may be class-specific, directed against the alpha
heavy chain, or type-specific, directed against the heavy
chain subclass. People with normal or deficient levels of
IgA may make antibodies to the heavy chain subclass
that they do not possess (two antigenically distinct sub-
classes exist). The anti-IgA that causes these reactions is
almost always a potent IgG or IgM antibody, not IgE anti-
body. Occasionally, other antibodies can be the cause,
such as those directed at soluble plasma proteins or
drugs such as penicillin.22
The severity and rapid onset of this reaction illustrates
the importance of the transfusionist staying with the
patient during the first 15 minutes of the transfusion.
The blood component must be stopped immediately
and the hypotension vigorously treated. Epinephrine
subcutaneously administered early in the course of treat-
ment is vital. Known IgA-deficient patients with anti-IgA
should receive blood without IgA. Deglycerolized or
extensively washed RBCs will suffice. If components
with plasma are needed, there is no other alternative;
IgA-negative products from an IgA-deficient donor must
be provided. 
Cutaneous hypersensitivity or allergic reactions com-
monly cause urticaria and local erythema in the absence
of fever. The allergies may be to plasma proteins. These
reactions are mild and occur commonly. It is sensible to
salvage the blood component, rather than increasing
donor exposure by discarding it and transfusing anoth-
er product. The transfusion may be paused while an
antihistamine is administered, then restarted when the
symptoms subside. Judgment must be practiced; if the
reaction involves systemic signs, it might progress to an
anaphylactic reaction and should be stopped. If a
patient has a history of these reactions, pretreatment
with antihistamines is helpful. In patients with a history
of severe reactions, RBCs may be washed prior to trans-
fusion to remove plasma proteins.
Mild cutaneous hypersensitivity and anaphylaxis
most likely represent two ends of a spectrum. Antigen-
antibody interactions stimulate the release of histamine
from mast cells and basophils, and lead to the genera-
tion of complement-derived anaphylatoxins. Donor
basophils may cause the release of histamine into the
supernatant portion of stored blood components.23,24
However, it is unclear whether these levels of histamine
are enough to be clinically significant, and prestorage
leukocyte reduction can be helpful.25 Allergy or ana-
phylaxis that is generated in vivo will not be influenced
by leukocyte reduction.26
Transfusion-Related Acute Lung Injury
Transfusion-related acute lung injury (TRALI) results
from insult to the lungs and occurs in the few hours fol-
lowing a transfusion. Passive transfer of donor antibody
reacting with the recipient’s white cells is the usual
cause of TRALI. Therefore, any blood component con-
taining plasma can be implicated. Respiratory distress
develops with severe hypoxemia and the chest x-ray
will show pulmonary edema, but the patient is not in
heart failure or volume overload. Fever, chills, and
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donor has been found to have an antibody that causes
this complication, the transfusable product should be
restricted to washed or frozen RBCs, and the donor
should be deferred from donating products containing
plasma.
Bacterial Sepsis
Of the 355 deaths related to transfusion in the first 10
years of reporting to the FDA, 26 were caused by bac-
terial sepsis and 13 from platelet products.12 Yet bacte-
rial sepsis may be underestimated as an important cause
of transfusion-related morbidity and mortality. Chills,
high fever, and hypotension may rapidly progress to
endotoxin-mediated shock, with a mortality rate that
approaches 50 percent.33 Skin flora, such as
Staphylococcus epidermidis, diptheroids, Micrococcus,
and Sarcina species, are more likely to grow in platelets
that are stored at room temperature. Psychrophilic
organisms, those that grow in the cold and can utilize
citrate as a substrate for energy, are a significant hazard.
Some examples are Pseudomonas species, Yersinia
enterocolitica, Campylobacter, and Serratia species.33
Bacteria may contaminate the unit as a result of
incomplete cleansing of the phlebotomy site, be present
in the donor blood at the time of collection, be intro-
duced during preparation for transfusion, or exist in or
on the equipment used for collection. To confirm a sep-
tic reaction, cultures of the blood component and the
patient’s blood should grow the same organism. A gram
stain on the transfused component can be positive, but
if not, sepsis is not ruled out. In febrile reactions, it is
important to send the remainder of the component to
the blood bank so it can be cultured. These reactions
may seem like other febrile reactions at first, then
become more severe and progress to shock. It might not
always be clear which blood component was responsi-
ble if the transfusion was more than one unit. Thus, all
units would have to be investigated. Treatment includes
IV antibiotics and appropriate care for endotoxic shock
(fluids, vasopressors, etc.).
Yersinia enterocolitica is a psychrophilic organism
that can be present in donors who have a gastrointesti-
nal (GI) illness near the time of donation, or who are in
an iron overload state. Unfortunately, it also can be pre-
sent in asymptomatic donors. The Centers for Disease
Control (CDC) investigated seven cases of transfusion-
associated Y. enterocolitica between 1987 and 1989.34
All seven patients had received RBCs, and five died.
After an investigation identified the implicated donors,
hypotension are often present. The mechanism for the
injury and the reason it occurs in the lungs is unclear, but
it is believed that complement is activated and C5a, a
granulocyte chemotaxin, recruits these leukocytes to the
lungs. An animal model has suggested a requirement for
complement in the presence of an antigen-antibody reac-
tion.27 Damage from neutrophil lysosomal enzymes is
sustained in the endothelial wall followed by fluid enter-
ing the alveolar space. 
In a review of 36 cases, Popovsky and Moore28 find
that all reactions began within 4 hours of transfusion. All
patients required oxygen support, with most needing
mechanical ventilation, but 81 percent made a complete
recovery within 4 days. Two patients died and it was
believed that the episode of respiratory distress was a
contributing factor. In 89 percent of the cases, granulo-
cyte antibody or granulocyte and HLA antibodies were
found in the donors. 
In another series, Popovsky et al.29 discuss five
patients from the Mayo Clinic where leukoagglutinating
antibodies were found in the serum of one donor for
each patient. Four of the donors had HLA-specific anti-
bodies, and in three cases one antibody corresponded to
an HLA antigen in the recipient. Anti-NB230 and anti-
NA231, which are granulocyte-specific antibodies, as
well as anti-5b32, have all been documented in cases of
TRALI. In the latter, the corresponding antigen is from a
diallelic system (5a/5b) found on granulocytes, lympho-
cytes, and platelets. The anti-NB2 came from a female
donor with three children. She had donated blood 21
times, and TRALI had never occurred with her donated
blood even though the frequency of NB2 is 32 percent.
Despite the fact that there are many women with multi-
ple prior pregnancies in the donor pool, this type of
transfusion reaction is rare. In Popovsky and Moore’s
series of 36 patients, the majority of patients had
received general anesthesia, as did the patient with the
NA2 reaction. The patient who received the anti-NB2
had thrombotic thrombocytopenic purpura (TTP) and
was undergoing plasmapheresis.28
Van Buren et al.30 suggest that in all of the above situ-
ations, there may be hypoxic tissue damage that makes
patients more susceptible. This theory is important
because when patients have other sources of compro-
mise it is more likely that respiratory distress would be
attributed to the underlying illness. Yet, with aggressive
support, sometimes including steroids, respiratory dis-
tress is not only reversible, but normal lung function can
return. Thus, this reaction must be recognized. Once a
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testing for antibody against the specific strain found in
each case was performed, and six of the donors had the
appropriate serologic findings. Four reported a GI illness
in the month prior to donation, and one developed
symptoms the day he donated. Two donors denied any
illness, but one stated that household members had a GI
illness, which makes one suspect an asymptomatic
infection in the donor. This organism is a gram-negative
endotoxin-producing organism that begins to exhibit
logarithmic growth after a lag phase of up to 20 days in
RBCs stored at 4°C.35
Three cases of Serratia marcescens were found in
Denmark in 1991, all resulting from blood transfused
after collection into contaminated blood bags.36 In two
of the cases the fresh frozen plasma from the same dona-
tion was tested and found to be positive. This organism,
a gram-negative rod that occurs ubiquitously in soil, in
water, and on plant surfaces, was even able to survive
freezer temperatures.
Morrow et al.37 described a series of seven septic reac-
tions, one fatal, caused by PCs. The temperature elevations
in the patients were higher than those of FNHTRs, but
took as long as 4 hours to peak. This finding underscores
the need to return components to the blood bank after
febrile reactions. If they are thrown away, it is often too
late to retrieve the bag after a reaction declares itself as sep-
sis. Five of these infections were due to skin flora and,
interestingly, four of the PCs had been stored for 5 days.
Thus, these organisms may need to grow to high enough
concentrations before being able to cause infection. 
A number of studies have suggested that prestorage
WBC filtration is effective in reducing the likelihood of
Yersinia enterocolitica growth in RBCs; however, there
seems to be enough time needed for the WBCs to engulf
the organisms.38–41 These studies do not reach a con-
sensus on what amount of time is needed, what filters
are best, or at what stage during component preparation
filtration should take place. It is not known what effect
filtration will have on other organisms. However, in a
study by Wenz et al.,42 filtration of random-donor
platelet-rich plasma prior to the production of PCs was
not seen to cause any increase in the growth of several
organisms that commonly grow in this component.
Transfusion-Associated Graft-Versus-Host
Disease
Transfusion-associated graft-versus-host disease (TA-
GVHD) appears to be a more severe version of the graft-
versus-host disease that follows allogeneic bone marrow
transplant. These diseases share most symptoms, includ-
ing fever, skin rash, hepatitis, and watery or bloody diar-
rhea. The mechanism is the foreign T-lymphocytes
(graft), which engraft and begin to multiply in the trans-
fusion recipient (host) and attack “foreign” tissue. The
host usually is immunocompromised, as is the case in
bone marrow transplant recipients. In these transplant-
ed patients, however, the bone marrow is the graft, thus
this site is spared. In TA-GVHD the bone marrow is
affected, and pancytopenia results, accounting for the
greater severity. The disease onset is less than 30 days
from tranfusion. Any product rich in lymphocytes,
including RBCs, PCs, and granulocyte concentrates, can
be implicated. The mortality rate appears to be 85 per-
cent to 90 percent.43 Cytogenetic or HLA typing of the
patient’s lymphocytes after symptoms appear shows the
donor type, confirming that engraftment has taken
place.
Transfusion recipients who are immunocompro-
mised are at risk for this complication. Included are lym-
phopenic patients, patients being treated with
chemotherapy and irradiation, those with congenital
immune disorders, infants who received intrauterine
transfusion and need an exchange transfusion after
birth, and patients with Hodgkin’s disease. 
An understanding of another risk group has unfolded
in recent years. TA-GVHD occurred in 1986 in a
Japanese patient who was not believed to be immuno-
compromised.44 He was transfused with fresh blood 
following cardiac surgery. Other cases in immunocom-
petent recipients were also observed. Many occurred
following transfused components that were donated by
relatives. We now know that if the blood donor is
homozygous for one of the recipient’s HLA haplotypes,
the donor’s lymphocytes may not be recognized as for-
eign and destroyed, even in the face of a normal
immune system. Thus the transfused lymphocytes are
free to attack the host. There is a greater risk of this
occurrence if the blood product is from a relative or
from one member of a genetically homozygous popula-
tion to another. Using a mathematical model, Ohto et
al.45 showed the frequency of risk of transfusion of
blood from HLA homozygotes to HLA heterozygotes
with a shared haplotype in different population groups.
In American Caucasians, the risk for first-degree relatives
is 1 in 475, whereas unrelated persons have a risk of 1
in 7,174. In contrast, the Japanese risk among first-
degree relatives is 1 in 102, and unrelated persons have
a risk of 1 in 874.45
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No treatment influences the outcome in these
patients, and the focus is on prevention. Transfusion
recipients who are immunocompromised, receiving
blood from a relative, or receiving HLA-matched platelets
of an A or Bu grade should receive irradiated products.
The dose is 25 cGy.46 At this dose the effectiveness of
RBCs and platelets should not be adversely affected.47
At this time, the lower threshold for the number of
lymphocytes required to cause this reaction is unknown.
The only approved prevention is irradiation, and leuko-
cyte reduction is not appropriate for this use. However,
one study using an allogeneic mixed-lymphocyte reac-
tion as an in vitro model of TA-GVHD has shown encour-
aging results with the use of leukocyte reduction.48
Perhaps we will learn more about this subject in the
future.
Transfusion-Associated Circulatory Overload
Increases in blood volume, which are possible with
transfusion of any blood component, may result in cir-
culatory overload. Infants, the elderly, and those with
preexisting cardiac disease are more susceptible.
Chronic anemia is often compensated with an increased
plasma volume; therefore, transfusion in these individu-
als may result in volume overload. Patients exhibit dysp-
nea, a rapid increase in systolic blood pressure, and
pulmonary edema. The transfusion should be stopped
and therapy started with diuretics, oxygen, and mechan-
ical ventilation, if needed.
Strategies exist to prevent this outcome. Transfusions
in susceptible patients should proceed at a slow rate,
based on the degree of impairment. If the length of an
RBC transfusion needs to exceed 4 hours, the unit can
be issued from the blood bank in aliquots. Diuretics may
be administered prior to transfusion if necessary.
Pediatric patients requiring platelets, but unable to tol-
erate this volume, can have their PCs “super concentrat-
ed.”
A series from the Mayo Clinic showed that 1 in 708
patients transfused with RBCs developed circulatory
overload. This rate was observed during the years when
a transfusion consultation service was available. In the 7
years prior to the service’s availability, the rate of docu-
mented cases of TACO was only 1 in 3,168.49 This dif-
ference suggests that physicians need to be aware of the
risk of this complication.
Conclusion
Some transfusion reactions are avoidable; others are
not. Knowledge of the consequences discussed in this
article should prompt those who order blood to evalu-
ate the risks versus the benefits in all cases. The quick
recognition of transfusion reactions rests with the entire
patient care team. One point that is not new, but will
never be outdated, is that careful attention to procedure
is necessary—from the phlebotomist, to the blood bank
technical staff, to the transfusionist. Not deviating from
established procedures minimizes errors that otherwise
may lead to unnecessary and devastating consequences.
Potential strategies to treat or prevent some reactions
may appear in the future, such as blockage of the actions
of cytokines early in the course of acute hemolytic reac-
tions. With further study there may be enough justifica-
tion for wider application of prestorage leukocyte
reduction. In the meantime, positive results can be
achieved with awareness and attention to detail. 
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